Use of and Outcomes Related to Intrapleural Enzyme Therapy for Complicated Parapneumonic Effusion and Empyema in an Integrated Health System

ABOUT THIS EPISODE

Originally aired: April 1, 2026 

CHEST April 2026, Volume 169, Issue 4  

Eduardo Solbes, MD, joins CHEST^® Journal Podcast Moderator Matt Siuba, DO, MS, to discuss his research into the variation in full MIST2 regimen dosing of intrapleural enzyme therapy across 21 hospitals in adults hospitalized with complicated parapneumonic effusion or empyema. 

Disclaimer: The purpose of this activity is to expand the reach of CHEST content through awareness, critique, and discussion. All articles have undergone peer review for methodologic rigor and audience relevance. Any views asserted are those of the speakers and are not endorsed by CHEST. Listeners should be aware that speakers’ opinions may vary and are advised to read the full corresponding journal article(s) for complete context. This content should not be used as a basis for medical advice or treatment, nor should it substitute the judgment used by clinicians in the practice of evidence-based medicine. 

Moderator
Matt Siuba, DO, MS

Also available